Cholinesterase inhibitors are drugs used to treat certain medical conditions, such as Alzheimer’s and Parkinson’s diseases. They work by reducing the activity of cholinesterase, an enzyme responsible for breaking down acetylcholine (ACh), a neurotransmitter involved in sending messages from one nerve cell to another. By inhibiting the enzyme, cholinesterase inhibitors increase the amount of ACh available to be used by neurons, thus resulting in improved nerve conduction and improved cognitive function. Cholinesterase inhibitors come in two forms : reversible and irreversible. Reversible inhibitors temporarily bind to the enzyme for a short period of time, causing it to become temporarily unable to break down ACh. Irreversible inhibitors are more potent and are covalently, or permanently, bound to the enzyme, causing it to become permanently unable to break down ACh. The most commonly prescribed cholinesterase inhibitors are donepezil, rivastigmine and galantamine, which are reversible inhibitors. These drugs are primarily used to treat cognitive impairment associated with Alzheimer’s disease. They are thought to improve cognition by increasing synaptic concentrations of ACh, thus restoring the balance of neurotransmitters in the brain. In addition to treating Alzheimer’s disease, the cholinesterase inhibitors donepezil, rivastigmine and galantamine have also been used to treat other neurological conditions, such as Parkinson’s disease. These drugs are thought to work by increasing the availability of ACh, thus promoting better nerve conduction in the basal ganglia, the part of the brain that controls movement. Finally, the cholinesterase inhibitors donepezil, rivastigmine and galantamine have also been used to treat cognitive impairment in people with dementia. In many of these cases, the drugs have been found to improve memory, language and visual-spatial skills. Overall, cholinesterase inhibitors are a widely used class of drugs that work by increasing the availability of ACh, thereby improving cognitive function. Their effectiveness has been researched extensively and they are commonly used to treat Alzheimer’s disease, Parkinson’s disease and other forms of dementia.
Title : Perception and individuality in patient cases identifying the ongoing evolution of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Ken Ware, NeuroPhysics Therapy Institute, Australia
Title : Narrative medicine: A communication therapy for the communication disorder of Functional Seizures (FS) [also known as Psychogenic Non-Epileptic Seizures (PNES)]
Robert B Slocum, University of Kentucky HealthCare, United States
Title : Personalized and Precision Medicine (PPM), as a unique healthcare model through biodesign-driven biotech and biopharma, translational applications, and neurology-related biomarketing to secure human healthcare and biosafety
Sergey Victorovich Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Neuro sensorium
Luiz Moutinho, University of Suffolk, United Kingdom
Title : GBF1 inhibition reduces amyloid-beta levels in viable human postmortem Alzheimer's disease cortical explant and cortical organoid models
Sean J Miller, Yale School of Medicine, United States
Title : Traumatic Spinal Cord Injuries (tSCI) - Are the radiologically based “advances” in the management of the injured spine evidence-based?
W S El Masri, Keele University, United Kingdom